CD19 and neoplasm: First, γδ T cells engineered with CARs targeting specific antigens, such as GD2 or CD19, have demonstrated potent anti-tumor effects, including IFN-γ secretion and tumor cell cytotoxicity in both in vitro and in vivo models.